Cardiology in India with Dr Denis Xavier

View all posts »

#1: The burden of heart disease in India in 2012 with Dr Rajeev Gupta

Jul 26, 2012 16:20 EDT


In this inaugural episode, host Dr Denis Xavier (St John's National Academy of Health Sciences, Bangalore) and renowned academic Dr Rajeev Gupta (Fortis Escorts Hospital and Rajasthan University of Health Sciences, Jaipur) set the stage for the series with an overview of heart disease in India and its underlying risk factors. What explains the dramatic rise of cardiovascular disease and how is it being addressed?

See also:

 

Dr Gupta has served as an advisor or consultant for Merck. He has received grants for clinical research from the National Heart, Lung, and Blood Institute (US).

Dr Xavier has received research funding to his institution from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cadila Pharma, GlaxoSmithKline, Pfizer, Sanofi, and United Health. He has received peer-reviewed research grants from the National Institutes of Health (US), Wellcome Trust (UK), and Indian Council of Medical Research.





« Previous Post
#2: Policies to address cardiovascular disease in India with Dr Srinath Reddy
Oct 15, 2012 16:20 EDT



Your comments
#1: The burden of heart disease in India in 2012 with Dr Rajeev Gupta
# 1 of 7
July 27, 2012 12:19 (EDT)
Bob Harrington
Denis- Great to hear you doing this!  We look forward to hearing the thoughts from you and your colleagues on issues related to global cardiovascular health.  Good luck.  Bob
# 2 of 7
August 3, 2012 04:07 (EDT)
Kishan Vasekar

  good begining--I hadHeart attack followed by kidney failure and 40 days in ICU last year.

 I was well treated in Asian heart Institute mumbai.

  I think US protocols being followed are not apprpriate and care in silent hours even in

ICU is very very poor .We need to integrate Modern medicine and Ayurved in India .

Thanks 

 
# 3 of 7
August 4, 2012 03:52 (EDT)
S Rangan
Great work, congrats and best wishes for continual success. Would be good to get a status report on arrhythmia issues.
# 4 of 7
August 6, 2012 09:10 (EDT)
Jyothy Puthumana

 

Denis,

Great work !. All the best with continued excellence and for shedding the light on CV health in the Indian Subcontinent.

Jyothy 

 
# 5 of 7
September 19, 2012 09:32 (EDT)
Nimish Tolat (USA)
Thank you for an insightful, succint presentation on the state of Cardiac disease in India.
# 6 of 7
September 28, 2012 10:31 (EDT)
Prof.Dr.Sadasivan

Hi Dr Denis Xaviwr,

Good morning to you!

I congratulate you on this elucidation of India's imminent emergency in CVD realm.For helping you still further, I would like to introduce you to a Biotechnologist and researcher on CAD wall repair(tissue engineering and biuo materials) area.Her name is Surya.She has just finished her M.Phil in Biotechnology at the Sree Chitra Medical Clinical Research Institute here in Trivandrum.

Please contact her for a research write up on the work she has completed and demonstrated.Her email ID is surya.biotech88@gmail.com

I was able to appreciate her trailblazing work in tissue engineering only throughy her dissertation.

Sincerely yours,

Your brother in Christ,

Prof.Dr.Sadasivan (Niche Marketing Strategist and Language Expert)
# 7 of 7
October 11, 2012 04:46 (EDT)
GudaRaghava
I am seeing for more than some decades.Our intellectuals are carried away by rich nations along with their skills and contributions.The result of this is they are unable to develop LOW COST medicines and contribute their knowledge for the needy and poor.For example CLOPITAB and etc are not affordable for the BPL and even middle class Indians.I hope our Doctors realise this and contribute for the benefit of needy.Also I have observed the Hospitals are taking away lot of percentage from these SICK PATIENTS for the Devices,implants,Heart valves etc.The main portion of the Bill amount is not shared by the Doctor.Plan a way the Patient can have access directly from the manufacturer and some margin is left over for the Doctor.   

You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Forgot your username and/or password?
        Login        
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

    Join now for full access    
About the podcast
In this new series of podcasts, Dr Denis Xavier (St John's National Academy of Health Sciences, Bangalore) and his guests examine the burden of heart disease in India and a wide range of related topics of interest to Indian cardiologists, researchers, and the broader healthcare community--both at home and abroad.
About Dr Denis Xavier
Xavier is a physician and cardiology researcher from St John's Medical College and Research Institute, Bangalore, India, where he is professor and head of the Department of Pharmacology and Clinical Trials. In additional to his medical and postgraduate training, Xavier obtained a Master's in Clinical Epidemiology and Biostatistics from McMaster University, Canada.

With his senior colleague Dr Prem Pais (Dean, St John's Medical College), Dr Xavier set up the clinical trials unit at St John's and developed a network of collaboration with over 200 clinical research centers across India. This collaboration has facilitated 35 observational studies and large clinical trials in cardiology on different projects ranging from the polypill to the impact of nonmedical health workers in the prevention of CVD.

Xavier is lead author of the CREATE ACS registry paper (Lancet 2008), project director and coauthor of the Indian Polycap Study (TIPS) (Lancet 2009), and coinvestigator of the Wellcome Trust polypill. He is the primary investigator of the NIH-UH (USA) Center of Excellence at St John's, AMEND, Pfizer Preferred Research Center, as well as the Fogarty International Clinical Research Center.

Xavier has published widely and is a reviewer for numerous prestigious journals.